Chronic Hepatitis B Global Market Report 2025

Description

Chronic hepatitis B results from a prolonged infection with the hepatitis B virus (HBV), lasting more than six months. It can potentially cause severe liver damage, liver failure, or liver cancer. While often asymptomatic for years, it can be identified through blood tests and requires ongoing management with antiviral medications and regular monitoring.

In treating chronic hepatitis B, medications primarily consist of antivirals and immunomodulators. Antivirals are specifically designed to hinder the replication and growth of viruses. They play a crucial role in managing chronic hepatitis B by reducing the viral load in the liver and slowing the progression of liver damage.

The chronic hepatitis B market research report is one of a series of new reports from the business research company that provides chronic hepatitis B market statistics, including chronic hepatitis B industry global market size, regional shares, competitors with an chronic hepatitis B market share, detailed chronic hepatitis B market segments, market trends and opportunities, and any further data you may need to thrive in the chronic hepatitis B industry. This chronic hepatitis B market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic hepatitis B market size has grown steadily in recent years. It will grow from $3.77 billion in 2024 to $3.94 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to advances in antiviral therapy, growing government and NGO initiatives, improved diagnostic techniques, the rising prevalence of HIV, and increasing awareness.

The chronic hepatitis B market size is expected to see steady growth in the next few years. It will grow to $4.65 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to expansion in emerging markets, growing government policies and funding, improved diagnostics and screening, rising healthcare expenditure, increasing strategic collaborations and partnerships, a growing aging population, and growing public awareness campaigns. Major trends in the forecast period include a shift towards curative therapies, expansion in emerging markets, enhanced diagnostics and screening, partnerships and collaborations, and a focus on patient-centric care.

The high prevalence of chronic hepatitis B infection is expected to drive the growth of the chronic hepatitis B virus market in the future. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV) and can be prevented through vaccination. The rise in hepatitis B infection rates is largely due to low vaccination coverage, especially in low- and middle-income countries, leading to higher transmission rates as significant portions of the population remain unprotected. Increasing rates of hepatitis B infection are likely to boost demand for diagnostic tests and treatment options. For instance, according to a report published in June 2024 by the Centers for Disease Control and Prevention (CDC), a US-based government agency, increasing global hepatitis B vaccination coverage to 90% and treatment access to 80% could prevent 26 million new infections and 9 million deaths due to hepatitis B from 2022 to 2050. In 2022 alone, there were 1.2 million new cases of HBV infection. Consequently, the high prevalence of hepatitis B infection is expected to drive growth in the chronic hepatitis B virus market.

Leading companies in the chronic hepatitis B market are prioritizing technological advancements, such as novel antiviral therapies. These innovative therapies target viral infections, including resistant strains, by inhibiting viral replication and incorporating advanced delivery systems, with ongoing clinical trials assessing their safety and efficacy, such as bepirovirsen for chronic hepatitis B. For example, in February 2024, GSK plc, a UK-based multinational pharmaceutical and biotechnology company specializing in the research, development, manufacturing, and marketing of healthcare products, received the U.S. Food and Drug Administration (FDA) Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for chronic hepatitis B (CHB). Bepirovirsen is designed to degrade the RNA of the hepatitis B virus (HBV), potentially enabling the immune system to regain control over the infection. The drug has shown promising results in Phase IIb trials, specifically the B-Clear and B-Sure studies, where it demonstrated efficacy in reducing hepatitis B surface antigen (HBsAg) levels and achieving sustained viral suppression.

In November 2023, GSK plc, a pharmaceutical company headquartered in the UK, acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. The acquisition includes the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug. Through this acquisition, GSK aims to enrich its portfolio and reinforce its position in the treatment of chronic hepatitis B by introducing a promising new therapy. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson based in Belgium, specializes in developing treatments for a range of serious and complex diseases, including infectious diseases such as chronic hepatitis B.

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

North America was the largest region in the chronic hepatitis B market in 2024. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic hepatitis b market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic hepatitis B market consists of revenues earned by entities by providing services such as diagnostic testing, treatments, liver function monitoring, patient education, and support programs.The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic hepatitis B market also includes sales of medications, interferons, liver transplant medications, diagnostic kits, liver biopsy equipment, and HBV vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Hepatitis B Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic hepatitis b market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic hepatitis b ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic hepatitis b market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Antivirals; Immune Modulators
2) By Gender: Male; Female
3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers
Subsegments:
1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir); Interferons (Pegylated Interferon)
2) By Immune Modulators: Immune Checkpoint Inhibitors; Therapeutic Vaccines (HBV Vaccines Under Development)
Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche Ltd; Merck & Co Inc; Bristol-Myers Squibb Company; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r29783

1. Executive Summary

2. Chronic Hepatitis B Market Characteristics

3. Chronic Hepatitis B Market Trends And Strategies

4. Chronic Hepatitis B Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Chronic Hepatitis B Growth Analysis And Strategic Analysis Framework

5.1. Global Chronic Hepatitis B PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Chronic Hepatitis B Market Growth Rate Analysis
5.4. Global Chronic Hepatitis B Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Chronic Hepatitis B Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Chronic Hepatitis B Total Addressable Market (TAM)

6. Chronic Hepatitis B Market Segmentation

6.1. Global Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antivirals
Immune Modulators
6.2. Global Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Male
Female
6.3. Global Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Drug Stores And Retail Pharmacies
Online Providers
6.4. Global Chronic Hepatitis B Market, Sub-Segmentation Of Antivirals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nucleos(T)Ide Analogs (Tenofovir, Entecavir)
Interferons (Pegylated Interferon)
6.5. Global Chronic Hepatitis B Market, Sub-Segmentation Of Immune Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors
Therapeutic Vaccines (HBV Vaccines Under Development)

7. Chronic Hepatitis B Market Regional And Country Analysis

7.1. Global Chronic Hepatitis B Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Chronic Hepatitis B Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Hepatitis B Market

8.1. Asia-Pacific Chronic Hepatitis B Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Hepatitis B Market

9.1. China Chronic Hepatitis B Market Overview
9.2. China Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Hepatitis B Market

10.1. India Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Hepatitis B Market

11.1. Japan Chronic Hepatitis B Market Overview
11.2. Japan Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Hepatitis B Market

12.1. Australia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Hepatitis B Market

13.1. Indonesia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Hepatitis B Market

14.1. South Korea Chronic Hepatitis B Market Overview
14.2. South Korea Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Hepatitis B Market

15.1. Western Europe Chronic Hepatitis B Market Overview
15.2. Western Europe Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Hepatitis B Market

16.1. UK Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Hepatitis B Market

17.1. Germany Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Hepatitis B Market

18.1. France Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Hepatitis B Market

19.1. Italy Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Hepatitis B Market

20.1. Spain Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Hepatitis B Market

21.1. Eastern Europe Chronic Hepatitis B Market Overview
21.2. Eastern Europe Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Hepatitis B Market

22.1. Russia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Hepatitis B Market

23.1. North America Chronic Hepatitis B Market Overview
23.2. North America Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Hepatitis B Market

24.1. USA Chronic Hepatitis B Market Overview
24.2. USA Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Hepatitis B Market

25.1. Canada Chronic Hepatitis B Market Overview
25.2. Canada Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Hepatitis B Market

26.1. South America Chronic Hepatitis B Market Overview
26.2. South America Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Hepatitis B Market

27.1. Brazil Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Hepatitis B Market

28.1. Middle East Chronic Hepatitis B Market Overview
28.2. Middle East Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Hepatitis B Market

29.1. Africa Chronic Hepatitis B Market Overview
29.2. Africa Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Hepatitis B Market Competitive Landscape And Company Profiles

30.1. Chronic Hepatitis B Market Competitive Landscape
30.2. Chronic Hepatitis B Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Hepatitis B Market Other Major And Innovative Companies

31.1. GlaxoSmithKline plc
31.2. Dynavax Technologies Corporation
31.3. Gilead Sciences Inc
31.4. Viatris Inc.
31.5. Teva Pharmaceutical Industries Limited
31.6. Sun Pharmaceutical Industries Ltd.
31.7. Aurobindo Pharma Limited
31.8. Dr. Reddy's Laboratories Ltd.
31.9. Apotex Corp
31.10. Cipla Ltd
31.11. Hikma Pharmaceuticals
31.12. Lupin Pharmaceuticals Inc
31.13. Vir Biotechnology Inc
31.14. VBI Vaccines Inc
31.15. Shenzhen Hepalink Pharmaceutical Co. Ltd.

32. Global Chronic Hepatitis B Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Hepatitis B Market

34. Recent Developments In The Chronic Hepatitis B Market

35. Chronic Hepatitis B Market High Potential Countries, Segments and Strategies

35.1 Chronic Hepatitis B Market In 2029 - Countries Offering Most New Opportunities
35.2 Chronic Hepatitis B Market In 2029 - Segments Offering Most New Opportunities
35.3 Chronic Hepatitis B Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer